Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function
Sung, E. Z. H., Arasaradnam, Ramesh P., Jarvie, E. M., James, Sean, Goodyear, S. J., Borman, R. A., Snead, David, Sanger, G. J. and Nwokolo, Chuka U.. (2012) Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Molecular Biology Reports, Vol.39 (No.12). pp. 9989-9994. ISSN 0301-4851
WRAP_ARarasadnam_Gastric_chemo_ motility_paper-13-ejc_October 2011_RPA.pdf - Accepted Version
Restricted to Repository staff only until 1 January 2014.
Official URL: http://dx.doi.org/10.1007/s11033-012-1866-7
Delayed gastric emptying symptoms are often reported after chemotherapy. This study aims to characterise the effects of chemotherapy on gastric neuro-muscular function. Patients undergoing elective surgery for oesophago-gastric cancer were recruited. Acetylcholinesterase, nNOS, ghrelin receptor and motilin expressions were studied in gastric sections from patients receiving no chemotherapy (n = 3) or oesophageal (n = 2) or gastric (n = 2) chemotherapy. A scoring system quantified staining intensity (0–3; no staining to strong). Stomach sections were separately suspended in tissue baths for electrical field stimulation (EFS) and exposure to erythromycin or carbachol; three patients had no chemotherapy; four completed cisplatin-based chemotherapy within 6 weeks prior to surgery. AChE expression was markedly decreased after chemotherapy (scores 2.3 ± 0.7, 0.5 ± 0.2 and 0 ± 0 in non-chemotherapy, oesophageal- and gastric-chemotherapy groups (p < 0.03 each) respectively. Ghrelin receptor and motilin expression tended to increase (ghrelin: 0.7 ± 0.4 vs 2.0 ± 0.4 and 1.2 ± 0.2 respectively; p = 0.04 and p = 0.2; motilin: 0.7 ± 0.5 vs 2.2 ± 0.5 and 2.0 ± 0.7; p = 0.06 and p = 0.16). Maximal contraction to carbachol was 3.7 ± 0.7 g and 1.9 ± 0.8 g (longitudinal muscle) and 3.4 ± 0.4 g and 1.6 ± 0.6 (circular) in non-chemotherapy and chemotherapy tissues respectively (p < 0.05 each). There were loss of AChE and reduction in contractility to carbachol. The tendency for ghrelin receptors to increase suggests an attempt to upregulate compensating systems. Our study offers a mechanism by which chemotherapy markedly alters neuro-muscular gastric function.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences|
|Library of Congress Subject Headings (LCSH):||Drugs -- Side effects, Esophagus -- Cancer -- Chemotherapy, Stomach -- Cancer -- Chemotherapy, Stomach -- Physiology|
|Journal or Publication Title:||Molecular Biology Reports|
|Page Range:||pp. 9989-9994|
|Access rights to Published version:||Restricted or Subscription Access|
|References:||2002, "Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial", Lancet, vol. 359, no. 9319, pp. 1727-1733. Aggarwal, S. K., San Antonio, J. D., Sokhansanj, A., & Miller, C. 1994, "Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation", Anticancer Drugs, vol. 5, no. 2, pp. 177-193. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van, d., V, Nicolson, M. et al "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N.Engl.J.Med., vol. 355, no. 1, pp. 11-20. Hursti, T. J., Borjeson, S., Hellstrom, P. M., vall-Lundqvist, E., Stock, S., Steineck, G et al . 2005, "Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting", Scand.J.Gastroenterol., vol. 40, no. 6, pp. 654-661. Inui, A., Asakawa, A., Bowers, C. Y., Mantovani, G., Laviano, A., Meguid, M. M. et al. 2004, "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ", FASEB J., vol. 18, no. 3, pp. 439-456. Jarve, R. K. & Aggarwal, S. K. 1997, "Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention", Cancer Chemother.Pharmacol., vol. 39, no. 4, pp. 341-348. Liu, Y. L., Malik, N. M., Sanger, G. J., & Andrews, P. L. 2006, "Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents", Cancer Chemother.Pharmacol., vol. 58, no. 3, pp. 326-333. Malik, N. M., Moore, G. B., Kaur, R., Liu, Y. L., Wood, S. L., Morrow, R. W. et al. 2008, "Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia", Regul.Pept., vol. 148, no. 1-3, pp. 33-38. Nagahama, S., Korenaga, D., Honda, M., Inutsuka, S., & Sugimachi, K. 2002, "Assessment of the intestinal permeability after a gastrectomy and the oral administration of anticancer drugs in rats: nitric oxide release in response to gut injury", Surgery, vol. 131, no. 1 Suppl, p. S92-S97. Nelson, K., Walsh, D., & Sheehan, F. 2002, "Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients", Support.Care Cancer, vol. 10, no. 6, pp. 455-461. Riezzo, G., Clemente, C., Leo, S., & Russo, F. 2005, "The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms", J.Gastroenterol., vol. 40, no. 12, pp. 1107-1115. Sanger, G. J. 2008, "Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases", Drug Discov.Today, vol. 13, no. 5-6, pp. 234-239. Wang, Y. & Aggarwal, S. K. 1997, "Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity", Anticancer Drugs, vol. 8, no. 9, pp. 853-858.|
Actions (login required)